WO1999000494A3 - Procede d'activation de cellule et reactifs a cet effet - Google Patents

Procede d'activation de cellule et reactifs a cet effet Download PDF

Info

Publication number
WO1999000494A3
WO1999000494A3 PCT/GB1998/001842 GB9801842W WO9900494A3 WO 1999000494 A3 WO1999000494 A3 WO 1999000494A3 GB 9801842 W GB9801842 W GB 9801842W WO 9900494 A3 WO9900494 A3 WO 9900494A3
Authority
WO
WIPO (PCT)
Prior art keywords
activation process
cell activation
reagents therefor
cell
receptor
Prior art date
Application number
PCT/GB1998/001842
Other languages
English (en)
Other versions
WO1999000494A2 (fr
Inventor
Helene Margaret Finney
Alastair David Griffith Lawson
Andrew Neil Charles Weir
Original Assignee
Celltech Therapeutics Ltd
Helene Margaret Finney
Alastair David Griffith Lawson
Andrew Neil Charles Weir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech Therapeutics Ltd, Helene Margaret Finney, Alastair David Griffith Lawson, Andrew Neil Charles Weir filed Critical Celltech Therapeutics Ltd
Priority to AU81210/98A priority Critical patent/AU8121098A/en
Priority to JP50537099A priority patent/JP2002511757A/ja
Priority to EP98930934A priority patent/EP1002073A2/fr
Publication of WO1999000494A2 publication Critical patent/WO1999000494A2/fr
Publication of WO1999000494A3 publication Critical patent/WO1999000494A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70507—CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne un procédé d'activation de cellule dans lequel une cellule effectrice est transformée avec un ADN codant un récepteur chimère contenant deux ou plusieurs composants de signalisation cytoplasmiques différents. Au moins un des composants de signalisation cytoplasmiques est dérivé de tout ou d'une partie d'une protéine transmembranaire à tétra couverture, CD43, CD6, d'un mannose, IL-7, IL-12 ou d'un récepteur du complément, d'une protéine associée à l'intégrine, ou d'une chaîne η associée à un récepteur de cytokine. La cellule activée peut s'utiliser dans le domaine médical, par exemple dans le traitement de maladies telles que le cancer.
PCT/GB1998/001842 1997-06-25 1998-06-24 Procede d'activation de cellule et reactifs a cet effet WO1999000494A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU81210/98A AU8121098A (en) 1997-06-25 1998-06-24 Cell activation process and reagents therefor
JP50537099A JP2002511757A (ja) 1997-06-25 1998-06-24 細胞活性化プロセスおよびそのための試薬
EP98930934A EP1002073A2 (fr) 1997-06-25 1998-06-24 Procede d'activation de cellule et reactifs a cet effet

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9713473.8 1997-06-25
GBGB9713473.8A GB9713473D0 (en) 1997-06-25 1997-06-25 Biological products

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09446529 A-371-Of-International 2000-05-19
US10/280,596 Continuation US20030060444A1 (en) 1997-06-25 2002-10-24 Cell activation process and reagents therefor

Publications (2)

Publication Number Publication Date
WO1999000494A2 WO1999000494A2 (fr) 1999-01-07
WO1999000494A3 true WO1999000494A3 (fr) 1999-03-25

Family

ID=10814935

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1998/001842 WO1999000494A2 (fr) 1997-06-25 1998-06-24 Procede d'activation de cellule et reactifs a cet effet

Country Status (5)

Country Link
EP (1) EP1002073A2 (fr)
JP (1) JP2002511757A (fr)
AU (1) AU8121098A (fr)
GB (1) GB9713473D0 (fr)
WO (1) WO1999000494A2 (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9809658D0 (en) * 1998-05-06 1998-07-01 Celltech Therapeutics Ltd Biological products
GB9908816D0 (en) * 1999-04-16 1999-06-09 Celltech Therapeutics Ltd Biological product
GB9908814D0 (en) 1999-04-16 1999-06-09 Celltech Therapeutics Ltd Process
GB9908807D0 (en) * 1999-04-16 1999-06-09 Celltech Therapeutics Ltd Synthetic signalling molecules
GB9925848D0 (en) * 1999-11-01 1999-12-29 Celltech Therapeutics Ltd Biological products
US20030027763A1 (en) * 2001-06-07 2003-02-06 Rigel Pharmaceuticals, Incorporated CD43: modulators of mast cell degranulation
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
WO2007056812A1 (fr) * 2005-11-16 2007-05-24 Apollo Life Sciences Limited Molecule et molecules chimeres de celle-ci
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
BR122021026169B1 (pt) 2010-12-09 2023-12-12 The Trustees Of The University Of Pennsylvania Uso de uma célula
RU2708032C2 (ru) 2013-02-20 2019-12-03 Новартис Аг ЛЕЧЕНИЕ РАКА С ИСПОЛЬЗОВАНИЕМ ХИМЕРНОГО АНТИГЕНСПЕЦИФИЧЕСКОГО РЕЦЕПТОРА НА ОСНОВЕ ГУМАНИЗИРОВАННОГО АНТИТЕЛА ПРОТИВ EGFRvIII
WO2014130635A1 (fr) 2013-02-20 2014-08-28 Novartis Ag Ciblage efficace de la leucémie primaire humaine au moyen de lymphocytes t génétiquement modifiés des récepteurs d'antigènes chimériques anti-cd123
EP2970426B1 (fr) 2013-03-15 2019-08-28 Michael C. Milone Ciblage de cellules cytotoxiques par des récepteurs chimériques pour une immunothérapie adoptive
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
CA3225453A1 (fr) 2013-12-19 2015-06-25 Novartis Ag Recepteurs antigeniques chimeriques de la mesotheline humaine et leurs utilisations
EP3087101B1 (fr) 2013-12-20 2024-06-05 Novartis AG Récepteur d'antigène chimérique régulable
WO2015112626A1 (fr) 2014-01-21 2015-07-30 June Carl H Capacité améliorée de présentation de l'antigène de lymphocytes t de récepteur d'antigène chimérique (car) par l'introduction conjointe de molécules de stimulation conjointe
HUE054588T2 (hu) 2014-04-07 2021-09-28 Novartis Ag Rák kezelése CD19 elleni, kiméra antigénreceptor alkalmazásával
CN106459914B (zh) 2014-05-15 2020-11-06 新加坡国立大学 经修饰的自然杀伤细胞及其用途
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
CA2955154C (fr) 2014-07-21 2023-10-31 Novartis Ag Traitement du cancer a l'aide du recepteur antigenique chimerique anti-cd33
MY181834A (en) 2014-07-21 2021-01-08 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
PL3183268T3 (pl) 2014-08-19 2020-09-07 Novartis Ag Chimeryczny receptor antygenowy (CAR) anty-CD123 do zastosowania w leczeniu nowotworu złośliwego
WO2016044605A1 (fr) 2014-09-17 2016-03-24 Beatty, Gregory Ciblage de cellules cytotoxiques avec des récepteurs chimériques pour l'immunothérapie adoptive
KR20170068504A (ko) 2014-10-08 2017-06-19 노파르티스 아게 키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도
IL253149B2 (en) 2014-12-29 2023-11-01 Novartis Ag Methods for preparing cells expressing a chimeric receptor antigen
WO2016115482A1 (fr) 2015-01-16 2016-07-21 Novartis Pharma Ag Promoteurs de phosphoglycérate kinase 1 (pgk) et procédés d'utilisation pour l'expression d'un récepteur antigénique chimérique
WO2016126608A1 (fr) 2015-02-02 2016-08-11 Novartis Ag Cellules exprimant car dirigées contre de multiples antigènes tumoraux et leurs utilisations
EP4056588A1 (fr) 2015-04-08 2022-09-14 Novartis AG Thérapies cd20, thérapies cd22 et thérapies combinées avec une cellule exprimant un récepteur d'antigène chimérique cd19 (car)
CA2982996A1 (fr) 2015-04-17 2016-10-20 David Maxwell Barrett Procedes pour ameliorer l'efficacite et l'expansion de cellules exprimant un recepteur antigenique chimerique
AU2016297014B2 (en) 2015-07-21 2021-06-17 Novartis Ag Methods for improving the efficacy and expansion of immune cells
WO2017027392A1 (fr) 2015-08-07 2017-02-16 Novartis Ag Traitement du cancer à l'aide des protéines de récepteur cd3 chimères
CN108780084B (zh) 2015-09-03 2022-07-22 诺华股份有限公司 预测细胞因子释放综合征的生物标志物
JP7082055B2 (ja) 2015-12-22 2022-06-07 ノバルティス アーゲー 抗癌治療における組み合わせ使用のためのメソテリンキメラ抗原受容体（ｃａｒ）およびｐｄ－ｌ１阻害剤に対する抗体
WO2017165683A1 (fr) 2016-03-23 2017-09-28 Novartis Ag Mini-corps sécrétés par des cellules et leurs usages
CN117866991A (zh) 2016-10-07 2024-04-12 诺华股份有限公司 用于治疗癌症的嵌合抗原受体
EP4043485A1 (fr) 2017-01-26 2022-08-17 Novartis AG Compositions de cd28 et procédés pour une thérapie à base de récepteur antigénique chimérique
RU2019133280A (ru) 2017-03-22 2021-04-22 Новартис Аг Композиции и способы для иммуноонкологии
MX2019011514A (es) 2017-03-27 2020-01-27 Nat Univ Singapore Receptores quimericos nkg2d truncados y usos de los mismos en inmunoterapia con celulas asesinas naturales.
KR20200086278A (ko) 2017-10-18 2020-07-16 노파르티스 아게 선택적 단백질 분해를 위한 조성물 및 방법
AU2019284911A1 (en) 2018-06-13 2020-12-17 Novartis Ag BCMA chimeric antigen receptors and uses thereof
WO2020180882A1 (fr) 2019-03-05 2020-09-10 Nkarta, Inc. Récepteurs d'antigènes chimériques anti-cd19 et leurs utilisations en immunothérapie
CN114945382A (zh) 2019-11-26 2022-08-26 诺华股份有限公司 Cd19和cd22嵌合抗原受体及其用途
WO2023081878A2 (fr) * 2021-11-08 2023-05-11 Baylor College Of Medicine Cellules immunitaires modifiées et leurs procédés d'utilisation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996023814A1 (fr) * 1995-02-03 1996-08-08 Cell Genesys, Inc. Molecules chimeres recepteur utilisees pour l'emission de signaux co-stimulateurs
WO1996024671A1 (fr) * 1995-02-06 1996-08-15 Cell Genesys, Inc. Recepteurs chimeres a specificites multiples
WO1997023613A2 (fr) * 1995-12-21 1997-07-03 Celltech Therapeutics Ltd. Procede d'activation de cellules et ses reactifs

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996023814A1 (fr) * 1995-02-03 1996-08-08 Cell Genesys, Inc. Molecules chimeres recepteur utilisees pour l'emission de signaux co-stimulateurs
WO1996024671A1 (fr) * 1995-02-06 1996-08-15 Cell Genesys, Inc. Recepteurs chimeres a specificites multiples
WO1997023613A2 (fr) * 1995-12-21 1997-07-03 Celltech Therapeutics Ltd. Procede d'activation de cellules et ses reactifs

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
MAECKER H.T. ET AL.: "The tetraspanin superfamily: molecular facilitators", THE FASEB JOURNAL, vol. 11, no. 6, May 1997 (1997-05-01), pages 428 - 442, XP002037857 *
OZAKI Y. ET AL.: "Anti-CD-9 monoclonal antibody activates p72syk in human platelets", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 25, 23 June 1995 (1995-06-23), pages 15119 - 15124, XP002079592 *
ROMEO C. ET AL.: "Activation of immune system effector function by T-cell or Fc receptor intracellular domains", COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY, vol. 57, 1992, pages 117 - 125, XP000647674 *
SHAW A.R.E. ET AL.: "Ectopic expression of human and feline CD9 in a human B cell line confers beta-1 Integrin-dependent motility on Fibronectin and Laminin substrates and enhanced tyrosine phosphorylation", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 41, 13 October 1995 (1995-10-13), pages 24092 - 24099, XP002079591 *
TOYO-OKA K. ET AL.: "Synergy between CD28 and CD9 costimulation for naive T-cell activation", IMMUNOLOGY LETTERS, vol. 58, no. 1, 1997, pages 19 - 23, XP002079593 *

Also Published As

Publication number Publication date
GB9713473D0 (en) 1997-09-03
AU8121098A (en) 1999-01-19
WO1999000494A2 (fr) 1999-01-07
JP2002511757A (ja) 2002-04-16
EP1002073A2 (fr) 2000-05-24

Similar Documents

Publication Publication Date Title
WO1999000494A3 (fr) Procede d'activation de cellule et reactifs a cet effet
WO1997023613A3 (fr) Procede d'activation de cellules et ses reactifs
WO1994011503A3 (fr) Facteur viii chimere
AU4512193A (en) Human nucleic acid fragments, isolated from brain adrenal tissue, placenta or bone narrow
WO1998025965A3 (fr) Peptides et composes qui se lient a un recepteur
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
WO1999053061A3 (fr) Acides nucleiques associes a des tumeurs et leur emploi
DE69736840D1 (de) Synthese von nukleosiden und polynukleotiden
AU8881201A (en) Tnf receptor-like molecules and uses thereof
WO1999051727A3 (fr) Sequences d'acides nucleiques humaines extraites des tissus sains d'ovaires
WO1998059040A3 (fr) Sous-unite de telomerase catalytique humaine et son utilisation therapeutique et diagnostique
WO2000029623A3 (fr) Acides nucleiques contenant des polymorphismes d'un seul nucleotide et utilisations de ces acides nucleiques
EP0642798A3 (fr) Molécules "platform" définis et de valence non-polymérique et leur conjugés
DE3576361D1 (de) Rekombinante dna, damit transformierter mikroorganismus, und verfahren zur herstellung von menschlicher cu-zn superoxiddismutase unter verwendung des transformierten mikroorganismus.
EP0910396A4 (fr) Molecules d'acide nucleique isolees codant pour un antigene gage de rejet tumoral, antigene de rejet tumoral et leurs utilisations
EP0749312A4 (fr) PROTEINES Gp29 DE -i(DIROFILARIA IMMITIS), MOLECULES D'ACIDE NUCLEIQUE ET LEURS UTILISATIONS
MXPA03000979A (es) Moleculas tipo receptor de complemento c3b/c4b y usos de las mismas.
EP1019092A4 (fr) Outils therapeutiques et diagnostiques pour desordres lies a une mauvaise tolerance glucidique
AU7508694A (en) Novel tyrosine kinase
WO1998051782A3 (fr) 3-hydroxyisobutyryl-coenzyme a hydrolase humaine
AU2347501A (en) Trp-protein-related mtr1 protein and dna sequence coding therefor
WO1998041538A3 (fr) Nouvelle proteine receptrice des cytokines/steroides humaine
WO1996038556A3 (fr) Deltap62, ses variants, sequences d'acides nucleiques les codant, et leurs utilisations en therapie genique anti-cancereuse
WO1999000408A3 (fr) Nouvelle proteine transmembranaire humaine
ITTO940379A1 (it) Sequenze specifiche per il dna umano.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1998930934

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09446529

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1998930934

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1998930934

Country of ref document: EP